Terapevticheskii arkhivTerapevticheskii arkhivТерапевтический архив0040-36602309-5342LLC Obyedinennaya Redaktsiya6477510.26442/00403660.2021.02.200614ReviewsОбзорыResearch ArticleFeatures of intestinal microbiota disorders in the development of metabolic disorders in non-alcoholic fatty liver diseaseОсобенности нарушения кишечной микробиоты в развитии метаболических нарушений при неалкогольной жировой болезни печениhttps://orcid.org/0000-0002-6581-7017LivzanM. A.ЛивзанМария Анатольевна
Russian Federation

д.м.н., проф., зав. каф. факультетской терапии и гастроэнтерологии, ректор

mts-8-90@mail.ruhttps://orcid.org/0000-0002-7452-7230KrolevetsT. S.КролевецТатьяна Сергеевна
Russian Federation

к.м.н., доц. каф. факультетской терапии и гастроэнтерологии

mts-8-90@mail.ruhttps://orcid.org/0000-0001-7200-7082MozgovoyS. I.МозговойСергей Игоревич
Russian Federation

д.м.н., доц., проф. каф. патологической анатомии

mts-8-90@mail.ruhttps://orcid.org/0000-0002-3758-4930NikolaevN. A.НиколаевНиколай Анатольевич
Russian Federation

д.м.н., доц. каф. факультетской терапии и гастроэнтерологии

mts-8-90@mail.ruhttps://orcid.org/0000-0003-0149-6119NelidovaA. V.НелидоваАнастасия Владимировна
Russian Federation

к.м.н., доц. каф. пропедевтики внутренних болезней

mts-8-90@mail.ruOmsk State Medical UniversityФГБОУ ВО «Омский государственный медицинский университет» Минздрава России150220219322222270504202105042021Copyright ©; 2021, Consilium MedicumCopyright ©; 2021, ООО "Консилиум Медикум"2021Consilium MedicumООО "Консилиум Медикум"https://creativecommons.org/licenses/by-nc-sa/4.0https://ter-arkhiv.ru/0040-3660/article/view/64775

We discussed about the term “intestinal permeability” like as the mucosal barrier – a single structural and functional conception that includes the layer of mucus, the indigenous microbiota and the epithelium of the mucosa in this publication. Information was presented about the role of the microbiota, the composition of intestinal mucus, epithelial cells and proteins of tight junctions which lead to various metabolic diseases. The complex pathogenetic interactions are formed between the intestinal mucosal barrier, metabolic disorders such as non-alcoholic fatty liver disease and cardiovascular diseases. The complex researches and modification of this interactions will allow to create personalized approaches and to prevent of these diseases.

В обзоре рассмотрена кишечная проницаемость с позиций мукозального барьера – единой структурно-функциональной единицы, включающей пристеночный слой слизи, индигенную микробиоту и эпителий слизистой оболочки. Представлены данные о том, что нарушения микробиоты, состава кишечной слизи, эпителиоцитов и белков плотных контактов приводят к различным метаболическим сдвигам. Таким образом формируются сложные патогенетические взаимодействия между интестинальным мукозальным барьером, метаболическими нарушениями, такими как неалкогольная жировая болезнь печени, и сердечно-сосудистыми заболеваниями, комплексное изучение и модификация которых позволит проводить персонифицированную терапию и профилактику данных заболеваний.

intestinal mucosal barriermetabolic continuumcardiovascular risksинтестинальный мукозальный барьерметаболический континуумкардиоваскулярные рискиГрант Президента РФ для государственной поддержки ведущих научных школ 2020 (ШН-2020) «Разработка технологии здоровьесбережения коморбидного больного гастроэнтерологического профиля на основе критериев приверженности» (прикладная) №ГР АААА-А20-120040790011-1 от 07.04.2020Fialho A, Fialho A, Kochhar G, et al. Association Between Small Intestinal Bacterial Overgrowth by Glucose Breath Test and Coronary Artery Disease. Dig Dis Sci. 2018;63(2):412–21. doi: 10.1007/s10620-017-4828-z.Groschwitz KR, Hogan SP. Intestinal barrier function: molecular regulation and disease pathogenesis. J Allergy Clin Immunol. 2009;124:3-20. doi: 10.1016/j.jaci.2009.05.038Wada M, Tamura A, Takahashi N, Tsukita S. Loss of claudins 2 and 15 from mice causes defects in paracellular Na + flow and nutrient transport in gut and leads to death from malnutrition. Gastroenterology. 2013;144:369-80. doi: 10.1053/j.gastro.2012.10.035Tsukita S, Furuse M, Itoh M. Multifunctional strands in tight junctions. Nat Rev Mol Cell Biol. 2001;2:285-93. doi: 10.1038/35067088Ulluwishewa D, Anderson RC, McNabb WC, et al. Regulation of tight junction permeability by intestinal bacteria and dietary components. J Nutr. 2011;141:769-76. doi: 10.3945/jn.110.135657Turner JR. Intestinal mucosal barrier function in health and disease. Nat Rev Immunol. 2009;9:799-809. doi:10.1038/nri2653Johansson ME, Thomsson KA, Hansson GC. Proteomic analyses of the two mucus layers of the colon barrier reveal that their main component, the Muc2 mucin, is strongly bound to the Fcgbp protein. J Proteome Res. 2009;8:3549-57. doi: 10.1021/pr9002504Bäckhed F, Ley RE, Sonnenburg JL, et al. Host-bacterial mutualism in the human intestine. Science. 2005;307:1915-20. doi: 10.1126/science.1104816Eckburg PB, Bik EM, Bernstein CN, et al. Diversity of the human intestinal microbial flora. Science. 2005;308:1635-8. doi: 10.1126/science.1110591Ley RE, Hamady M, Lozupone C, et al. Evolution of mammals and their gut microbes. Science. 2008;320:1647-51. doi: 10.1126/science.1155725Arumugam M, Raes J, Pelletier E, et al. Enterotypes of the human gut microbiome. Nature. 2011;473:174-80. doi: 10.1038/nature09944Rinninella E, Raoul P, Cintoni M, et al. What is the Healthy Gut Microbiota Composition? A Changing Ecosystem across Age, Environment, Diet, and Diseases. Microorganisms. 2019;7(1):14. doi: 10.3390/microorganisms7010014Johnston DG, Corr SC. Toll-Like Receptor Signalling and the Control of Intestinal Barrier Function. Methods Mol Biol. 2016;1390:287-300. doi: 10.1007/978-1-4939-3335-8_18Bischoff SC, Barbara G, Buurman W, et al. Intestinal permeability – a new target for disease prevention and therapy. BMC Gastroenterology. 2014;14:189. Available at: http://www.biomedcentral.com/1471-230X/14/189Ahmad R, Rah B, Bastola D, et al. Obesity-induces Organ and Tissue Specific Tight Junction Restructuring and Barrier Deregulation by Claudin Switching. Sci Rep. 2017;7(1):5125. doi: 10.1038/s41598-017-04989-8Loomba R, Seguritan V, Li W, et al. Gut microbiome-based metagenomic signature for non-invasive detection of advanced fibrosis in human nonalcoholic fatty liver disease. Cell Metab. 2017;25:1054-62.e1-e5. doi: 10.1016/j.cmet.2017.04.001Jayakumar S, Loomba R. Review article: emerging role of the gut microbiome in the progression of nonalcoholic fatty liver disease and potential therapeutic implications. Aliment Pharmacol Ther. 2019;50:144-58. doi: 10.1111/apt.15314Duseja A, Acharya SK, Mehta M, et al. High potency multistrain probiotic improves liver histology in nonalcoholic fatty liver disease (NAFLD): a randomised, double-blind, proof of concept study. BMJ Open Gastro. 2019;6:e000315. doi: 10.1136/ bmjgast-2019-000315Jayakumar S, Loomba R. Review article: emerging role of the gut microbiome in the progression of non alcoholic fatty liver disease and potential therapeutic implications. Aliment Pharmacol Ther. 2019;50:144-58. doi: 10.1111/apt.15314Geurts L, Lazarevic V, Derrien M, et al. Altered gut microbiota and endocannabinoid system tone in obese and diabetic leptin-resistant mice: Impact on apelin regulation in adipose tissue. Front Microbiol. 2011;2:149. doi: 10.3389/fmicb.2011.00149Rizzatti G, Lopetuso LR, Gibiino G, et al. Proteobacteria: A common factor in human diseases. Biomed Res Int. 2017;2017:9351507. doi: 10.1155/2017/9351507Brown JM, Hazen SL. Microbial modulation of cardiovascular disease. Nat Rev Microbiol. 2018;16:171-81. doi: 10.1038/nrmicro.2017.149Yamashita T. Intestinal Immunity and Gut Microbiota in Atherogenesis. J Atheroscler Thromb. 2017;24:110-9. doi: 10.5551/jat.38265Al-Obaide MAI, Singh R, Datta P, et al. Gut Microbiota-Dependent Trimethylamine-N-oxide and Serum Biomarkers in Patients with T2DM and Advanced CKD. J Clin Med. 2017;6(9):1-13. doi: 10.3390/jcm6090086Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. World Gastroenterology Organisation Global Guidelines. June 2012. Available at: http://www.worldgastroenterology.org/NAFLD-NASH.htmlМаев И.В., Андреев Д.Н., Кучерявый Ю.А. и др. Неалкогольная жировая болезнь печени с позиций современной медицины: учеб. пособие. М.: Прима Принт, 2020 [Maev IV, Andreev DN, Kucheriavyi IuA, et al. Non-alcoholic fatty liver disease from the standpoint of modern medicine: a tutorial. Moscow: Prima Print, 2020 (In Russ.)].Dulai PS, Singh S, Patel J, et al. Increased risk of mortality by fibrosis stage in non-alcoholic fatty liver disease: Systematic Review and Meta-analysis. Hepatology. 2017;65(5):1557-65. doi: 10.1002/hep.29085Sharma M, Mitnala S, Vishnubhotla RK, et al. The Riddle of Nonalcoholic Fatty Liver Disease: Progression from Nonalcoholic Fatty Liver to Nonalcoholic Steatohepatitis. J Clin Exp Hepatol. 2015;5:147-58. doi: 10.1016/j.jceh.2015.02.002Maev IV, Samsonov AA, Palgova LK, et al. Effectiveness of phosphatidylcholine in alleviating steatosis in patients with non-alcoholic fatty liver disease and cardiometabolic comorbidities (MANPOWER study). BMJ Open Gastroenterol. 2020;7(1):e000341. doi: 10.1136/bmjgast-2019-000341Katsiki N, Mikhailidis DP, Mantzoros CS. Non-alcoholic fatty liver disease and dyslipidemia: An update. Metabolism. 2016;65:1109-23. doi: 10.1016/j.metabol.2016.05.003Маев И.В., Юренев Г.Л., Миронова Е.М., Юренева-Тхоржевская Т.В. Фенотип ожирения и гастроэзофагеальной рефлюксной болезни в контексте коморбидности у больных с сердечно-сосудистыми заболеваниями. Терапевтический архив. 2019;91(2):126-33 [Maev IV, Yurenev GL, Mironova EM, Yureneva-Thorzhevskaya TV. Phenotype of obesity and gastroesophageal reflux disease in the context of comorbidity in patients with cardiovascular diseases. Terapevticheskii Arkhiv (Ter. Arkh.). 2019;91(2):126-33 (In Russ.)]. doi: 10.26442/00403660.2019.02.000099Cabandugama PK, Gardner MJ, Sowers JR. The Renin Angiotensin Aldosterone System in Obesity and Hypertension: Roles in the Cardiorenal Metabolic Syndrome. Med Clin North Am. 2017;101:129-37. doi: 10.1016/j.mcna.2016.08.009Artunc F, Schleicher E, Weigert C, et al. The impact of insulin resistance on the kidney and vasculature. Nat Rev Nephrol. 2016;12:721-37. doi: 10.1038/nrneph.2016.145Ix JH, Sharma K. Mechanisms linking obesity, chronic kidney disease, and fatty liver disease: The roles of fetuin-A, adiponectin, and AMPK. J Am Soc Nephrol. 2010;21:406-12. doi: 10.1681/ASN.2009080820Ливзан М.А., Колбина М.В., Матошина И.В. и др. Гормоны жировой ткани и неалкогольная жировая болезнь печени при метаболическом синдроме. Дневник казанской мед. школы. 2014;1(4):44-8 [Livzan MA, Kolbina MV, Matoshina IV, et al. Hormones adipose tissue and non-alcoholic fatty liver disease at metabolic syndrome. Diary of Kazan Medical School. 2014;1(4):44-8 (In Russ.)]. Available at: https://readera.ru/140125975Stojsavljević S, Gomerčić Palčić M, Virović Jukić L, et al. Adipokines and proinflammatory cytokines, the key mediators in the pathogenesis of non-alcoholic fatty liver disease. World J Gastroenterol. 2014;20(48):18070-91. doi: 10.3748/wjg.v20.i48.18070Saxena NK, Anania FA. Anania Adipocytokines and hepatic fibrosis. Trends Endocrinol Metab. 2015;26(3):153-61. doi: 10.1016/j.tem.2015.01.002Pan H, Guo J, Su Z. Advances in understanding the interrelations between leptin resistance and obesity. Physiol Behav. 2014;130:157-69. doi: 10.1016/j.physbeh.2014.04.003Ливзан М.А., Лаптева И.В., Миллер Т.С. Роль лептина и лептинорезистентности в формировании неалкогольной жировой болезни печени у лиц с ожирением и избыточной массой тела. Экспериментальная и клиническая гастроэнтерология. 2014;108(8):27-33 [Livzan MA, Lapteva IV, Miller TS. Role leptin and leptinresistance to organization non-alcoholic fatty liver disease in persons with obesity and overweight. Eksperimental’naia i klinicheskaia gastroenterologiia. 2014;108(8):27-33 (In Russ.)].Ливзан М.А., Гаус О.В., Николаев Н.А., Кролевец Т.С. НАЖБП: коморбидность и ассоциированные заболевания. Экспериментальная и клиническая гастроэнтерология. 2019;170(10):57-65 [Livzan MA, Gaus OV, Nikolaev NA, Krolevetz TS. NAFLD: comorbidity and associated diseases. Eksperimental’naia i klinicheskaia gastroenterologiia. 2019;170(10):57-65 (In Russ.)]. doi: 10.31146/1682-8658-ecg-170-10-57-65Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol. 2004;5:987-95. doi: 10.1038/ni1112Heidemann J, Domschke W, Kucharzik T, Maaser C. Intestinal microvascular endothelium and immunity in inflammatory bowel disease: a secondline of defense? Infect Immun. 2006;74:5425-32. doi: 10.1128/iai.00248-06Faure E, Thomas L, Xu H, et al. Bacterial lipopolysaccharide and IFN-gamma induce Toll-like receptor 2 and Toll-like receptor 4 expression in human endothelial cells: role of NF-kappa B activation. J Immunol. 2001;166:2018-24.Shah V, Lyford G, Gores G, Farrugia G. Nitric Oxide in Gastrointestinal health and disease. J Gastroenterology. 2004;126:903-13. doi: 10.1053/j.gastro.2003.11.046Cibor D, Domagala-Rodacka R, Rodacki T et al. Endothelial dysfunction in inflammatory bowel diseases: Pathogenesis, assessment and implications. World J Gastroenterol. 2016;22(3):1067-77. doi: 10.3748/wjg.v22.i3.1067